US Stock MarketDetailed Quotes

BEAM Beam Therapeutics

Watchlist
  • 22.740
  • -0.730-3.11%
Close Apr 24 16:00 ET
  • 22.740
  • 0.0000.00%
Post 19:11 ET
1.87BMarket Cap-13220P/E (TTM)

Beam Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
(Q2)Jun 30, 2022
(Q1)Mar 31, 2022
Total revenue
520.01%377.71M
1,478.04%316.19M
8.82%17.19M
20.80%20.12M
187.10%24.21M
17.51%60.92M
-60.76%20.04M
1,970.64%15.8M
277,433.33%16.65M
140,433.33%8.43M
Operating revenue
520.01%377.71M
1,478.04%316.19M
8.82%17.19M
20.80%20.12M
187.10%24.21M
17.51%60.92M
-60.76%20.04M
1,970.64%15.8M
277,433.33%16.65M
140,433.33%8.43M
Cost of revenue
Gross profit
Operating expense
38.76%554.19M
68.16%183.33M
17.14%125.46M
23.98%122.26M
45.45%123.14M
-10.11%399.4M
-4.83%109.02M
52.14%107.1M
67.21%98.62M
-57.75%84.66M
Selling and administrative expenses
33.04%116.81M
90.72%43.26M
16.48%25.41M
2.47%24.66M
22.04%23.49M
53.45%87.81M
27.62%22.68M
38.30%21.82M
79.53%24.06M
87.36%19.25M
-General and administrative expense
33.04%116.81M
90.72%43.26M
16.48%25.41M
2.47%24.66M
22.04%23.49M
53.45%87.81M
27.62%22.68M
38.30%21.82M
79.53%24.06M
87.36%19.25M
Research and development costs
40.37%437.38M
62.24%140.08M
17.31%100.05M
30.92%97.61M
52.34%99.65M
-19.50%311.59M
-10.79%86.34M
56.14%85.29M
63.58%74.56M
-65.59%65.41M
Operating profit
47.86%-176.49M
249.30%132.86M
-18.58%-108.27M
-24.62%-102.15M
-29.78%-98.93M
13.76%-338.48M
-40.17%-88.99M
-31.12%-91.3M
-38.99%-81.97M
61.96%-76.23M
Net non-operating interest income expense
205.13%46.68M
58.51%12.06M
154.88%12.7M
480.24%11.95M
1,446.74%9.96M
170,066.67%15.3M
13,994.44%7.61M
55,255.56%4.98M
4,061.54%2.06M
3,166.67%644K
Non-operating interest income
----
----
154.88%12.7M
----
----
----
----
--4.98M
----
----
Total other finance cost
-205.13%-46.68M
----
----
-480.24%-11.95M
-1,446.74%-9.96M
-170,066.67%-15.3M
----
----
-4,061.54%-2.06M
-3,166.67%-644K
Other net income (expense)
-102.15%-1.35M
-101.72%-759K
-111.15%-519K
-6.75%7.42M
-217.68%-7.49M
188.53%63M
3,547.53%44.03M
-88.78%4.66M
146.18%7.96M
646.05%6.37M
Gain on sale of security
-125.15%-11.09M
-110.67%-2.62M
-217.90%-6.52M
-35.02%5.25M
-221.67%-7.2M
164.23%44.1M
685.24%24.58M
-82.10%5.53M
148.99%8.08M
786.99%5.92M
Special income (charges)
-48.48%9.74M
-90.42%1.86M
785.94%6M
1,909.17%2.17M
-165.49%-296K
267.35%18.9M
541.28%19.45M
-108.26%-875K
83.81%-120K
248.20%452K
-Less：Restructuring and merger&acquisition
48.48%-9.74M
90.42%-1.86M
-785.94%-6M
-1,909.17%-2.17M
165.49%296K
-267.35%-18.9M
-541.28%-19.45M
108.26%875K
-83.81%120K
-248.20%-452K
Income before tax
49.59%-131.16M
485.99%144.16M
-17.66%-96.09M
-15.05%-82.78M
-39.36%-96.46M
29.80%-260.18M
42.28%-37.35M
-190.44%-81.67M
5.64%-71.95M
65.66%-69.21M
Income tax
-59.94%1.37M
36.60%1.37M
0
3.41M
1M
2.41M
Earnings from equity interest net of tax
--0
--0
--0
----
----
---25.5M
--0
---25.5M
----
----
Net income
54.16%-132.53M
472.36%142.8M
12.31%-96.09M
-15.05%-82.78M
-39.36%-96.46M
22.00%-289.09M
40.73%-38.35M
-289.70%-109.58M
5.64%-71.95M
65.66%-69.21M
Net income continuous Operations
54.16%-132.53M
472.36%142.8M
12.31%-96.09M
-15.05%-82.78M
-39.36%-96.46M
22.00%-289.09M
40.73%-38.35M
-289.70%-109.58M
5.64%-71.95M
65.66%-69.21M
Minority interest income
Net income attributable to the parent company
54.16%-132.53M
472.36%142.8M
12.31%-96.09M
-15.05%-82.78M
-39.36%-96.46M
22.00%-289.09M
40.73%-38.35M
-289.70%-109.58M
5.64%-71.95M
65.66%-69.21M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
54.16%-132.53M
472.36%142.8M
12.31%-96.09M
-15.05%-82.78M
-39.36%-96.46M
22.00%-289.09M
40.73%-38.35M
-289.70%-109.58M
5.64%-71.95M
65.66%-69.21M
Basic earnings per share
58.35%-1.72
427.78%1.77
21.79%-1.22
-5.88%-1.08
-31.68%-1.33
28.42%-4.13
43.16%-0.54
-271.43%-1.56
17.07%-1.02
69.85%-1.01
Diluted earnings per share
58.35%-1.72
420.37%1.73
21.79%-1.22
-5.88%-1.08
-31.68%-1.33
28.42%-4.13
43.16%-0.54
-271.43%-1.56
17.07%-1.02
69.85%-1.01
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022(Q2)Jun 30, 2022(Q1)Mar 31, 2022
Total revenue 520.01%377.71M1,478.04%316.19M8.82%17.19M20.80%20.12M187.10%24.21M17.51%60.92M-60.76%20.04M1,970.64%15.8M277,433.33%16.65M140,433.33%8.43M
Operating revenue 520.01%377.71M1,478.04%316.19M8.82%17.19M20.80%20.12M187.10%24.21M17.51%60.92M-60.76%20.04M1,970.64%15.8M277,433.33%16.65M140,433.33%8.43M
Cost of revenue
Gross profit
Operating expense 38.76%554.19M68.16%183.33M17.14%125.46M23.98%122.26M45.45%123.14M-10.11%399.4M-4.83%109.02M52.14%107.1M67.21%98.62M-57.75%84.66M
Selling and administrative expenses 33.04%116.81M90.72%43.26M16.48%25.41M2.47%24.66M22.04%23.49M53.45%87.81M27.62%22.68M38.30%21.82M79.53%24.06M87.36%19.25M
-General and administrative expense 33.04%116.81M90.72%43.26M16.48%25.41M2.47%24.66M22.04%23.49M53.45%87.81M27.62%22.68M38.30%21.82M79.53%24.06M87.36%19.25M
Research and development costs 40.37%437.38M62.24%140.08M17.31%100.05M30.92%97.61M52.34%99.65M-19.50%311.59M-10.79%86.34M56.14%85.29M63.58%74.56M-65.59%65.41M
Operating profit 47.86%-176.49M249.30%132.86M-18.58%-108.27M-24.62%-102.15M-29.78%-98.93M13.76%-338.48M-40.17%-88.99M-31.12%-91.3M-38.99%-81.97M61.96%-76.23M
Net non-operating interest income expense 205.13%46.68M58.51%12.06M154.88%12.7M480.24%11.95M1,446.74%9.96M170,066.67%15.3M13,994.44%7.61M55,255.56%4.98M4,061.54%2.06M3,166.67%644K
Non-operating interest income --------154.88%12.7M------------------4.98M--------
Total other finance cost -205.13%-46.68M---------480.24%-11.95M-1,446.74%-9.96M-170,066.67%-15.3M---------4,061.54%-2.06M-3,166.67%-644K
Other net income (expense) -102.15%-1.35M-101.72%-759K-111.15%-519K-6.75%7.42M-217.68%-7.49M188.53%63M3,547.53%44.03M-88.78%4.66M146.18%7.96M646.05%6.37M
Gain on sale of security -125.15%-11.09M-110.67%-2.62M-217.90%-6.52M-35.02%5.25M-221.67%-7.2M164.23%44.1M685.24%24.58M-82.10%5.53M148.99%8.08M786.99%5.92M
Special income (charges) -48.48%9.74M-90.42%1.86M785.94%6M1,909.17%2.17M-165.49%-296K267.35%18.9M541.28%19.45M-108.26%-875K83.81%-120K248.20%452K
-Less：Restructuring and merger&acquisition 48.48%-9.74M90.42%-1.86M-785.94%-6M-1,909.17%-2.17M165.49%296K-267.35%-18.9M-541.28%-19.45M108.26%875K-83.81%120K-248.20%-452K
Income before tax 49.59%-131.16M485.99%144.16M-17.66%-96.09M-15.05%-82.78M-39.36%-96.46M29.80%-260.18M42.28%-37.35M-190.44%-81.67M5.64%-71.95M65.66%-69.21M
Income tax -59.94%1.37M36.60%1.37M03.41M1M2.41M
Earnings from equity interest net of tax --0--0--0-----------25.5M--0---25.5M--------
Net income 54.16%-132.53M472.36%142.8M12.31%-96.09M-15.05%-82.78M-39.36%-96.46M22.00%-289.09M40.73%-38.35M-289.70%-109.58M5.64%-71.95M65.66%-69.21M
Net income continuous Operations 54.16%-132.53M472.36%142.8M12.31%-96.09M-15.05%-82.78M-39.36%-96.46M22.00%-289.09M40.73%-38.35M-289.70%-109.58M5.64%-71.95M65.66%-69.21M
Minority interest income
Net income attributable to the parent company 54.16%-132.53M472.36%142.8M12.31%-96.09M-15.05%-82.78M-39.36%-96.46M22.00%-289.09M40.73%-38.35M-289.70%-109.58M5.64%-71.95M65.66%-69.21M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 54.16%-132.53M472.36%142.8M12.31%-96.09M-15.05%-82.78M-39.36%-96.46M22.00%-289.09M40.73%-38.35M-289.70%-109.58M5.64%-71.95M65.66%-69.21M
Basic earnings per share 58.35%-1.72427.78%1.7721.79%-1.22-5.88%-1.08-31.68%-1.3328.42%-4.1343.16%-0.54-271.43%-1.5617.07%-1.0269.85%-1.01
Diluted earnings per share 58.35%-1.72420.37%1.7321.79%-1.22-5.88%-1.08-31.68%-1.3328.42%-4.1343.16%-0.54-271.43%-1.5617.07%-1.0269.85%-1.01
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------Unqualified Opinion--------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg
Concept Gene Editing
Gene Editing
Intraday-1.01%